drugset / Trial / NCT00857428
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to demonstrate the relative bioequivalence of oxymorphone hydrochloride extended-release tablets (Sandoz) with Opana extended release oxymorphone hydrochloride tablets.
Timeline
- Start
- 2007-11
- Primary completion
- 2007-11
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxymorphone | Small molecule | 40 mg | — |
Indications
No indication recorded.